TG4050

DRUG2 trials

Sponsors

Transgene

Conditions

Fallopian Tube CancerOvarian CarcinomaPeritoneal CarcinomaSquamous Cell Carcinoma of Head and Neck

Phase 1

A Trial Evaluating TG4050 in Ovarian Carcinoma.

CompletedNCT03839524

TransgeneFallopian Tube Cancer, Ovarian Carcinoma, Peritoneal Carcinoma

Start: 2019-12-09End: 2024-10-08Updated: 2025-11-14

A Clinical Trial Evaluating TG4050 in Head and Neck Cancer

Active, not recruitingNCT04183166

TransgeneSquamous Cell Carcinoma of Head and Neck

Start: 2019-12-12End: 2031-12-30Updated: 2026-01-16

Related Papers

A viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: a randomized Phase I trial

Nature Communications2026-08-17

Randomized phase I trial of adjuvant personalized cancer vaccine TG4050 in resected locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) patients (pts).

Journal of Clinical Oncology2025-05-281 citations

Safety and immunogenicity of TG4050: A personalized cancer vaccine in head and neck carcinoma.

Journal of Clinical Oncology2023-06-018 citations

Abstract LB205: Feasibility and immunogenicity of adjuvant TG4050, a patient tailored cancer vaccine in head and neck and ovarian cancer

Cancer Research2023-04-141 citations

Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and neck squamous cell carcinoma (HNSCC).

Journal of Clinical Oncology2022-06-018 citations

Abstract 4566: Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine

Cancer Research2020-08-151 citations